Hematologic Malignancies
Research activity is concentrated in relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, mature B-cell neoplasms, and CD19-positive or CD20-positive B-cell malignancies. The portfolio also includes acute myeloid leukemia and pediatric as well as adult forms of aggressive B-cell disease.
- Diffuse large B-cell lymphoma
- Relapsed or refractory B-cell non-Hodgkin lymphoma
- CD19-positive B-cell malignancies
- Acute myeloid leukemia
These studies reflect a strong focus on cell therapy approaches for difficult-to-treat blood cancers, including settings with prior treatment failure.
Systemic Autoimmune Disease
The sponsor is active in systemic lupus erythematosus, refractory systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy. The research emphasis is on severe B-cell mediated autoimmune disease with persistent immune activation.
- Systemic lupus erythematosus
- Systemic sclerosis
- Idiopathic inflammatory myopathy
- Refractory autoimmune disease
Clinical interest in this area centers on immune modulation in patients with active disease that remains difficult to control with standard treatment.
Cell and Gene Therapy
The trial portfolio includes CAR-T cell therapy and other cell and gene therapies developed for both malignant and autoimmune indications. Key programs involve MB-CART2019.1, MB-CART19.1, and related engineered cellular products.
- CAR-T cell therapy
- Engineered T-cell products
- Long-term safety follow-up
- Relapsed or refractory disease
Research in this domain spans both oncology and autoimmune disease, with attention to treatment durability and safety.
Multiple Sclerosis and Melanoma
The sponsor also funds studies in refractory multiple sclerosis and unresectable stage III or IV melanoma, extending its clinical interests beyond hematology and systemic autoimmunity.
- Refractory multiple sclerosis
- Unresectable melanoma
- Advanced immune-mediated disease
These programs indicate involvement in challenging neurologic and oncologic conditions where novel immune-based therapies are being explored.
